{"url_path":"/sec/silo/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-063185-index.html","accession_number":"0001213900-26-063185","cik":"0001514183","ticker":"SILO","issuer_name":"Silo Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-063185-index.html","primary_entity_key":"0001514183","primary_entity_name":"Silo Pharma, Inc."},"word_count":308,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n \n\nSilo Pharma, Inc. (the\n“Company”) today announced that it will effect a 1-for-15 reverse split of its issued and outstanding common stock with a\nconcurrent proportionate reduction of its authorized common stock effective as of 4:01 p.m. Eastern Time on June 2, 2026. Commencing\nwith the opening of trading on The Nasdaq Capital Market on June 3, 2026, the Company’s common stock will trade on a\npost-split basis under the same trading symbol, “SILO”.\n\n \n\nAs a result of the reverse stock split, the CUSIP\nnumber for the Company’s common stock will be 82711P 300 and every fifteen (15) shares of issued and outstanding Company common\nstock will be exchanged for one (1) share of Company common stock with any fractional shares being rounded up to the next higher whole\nshare. Once effective, the reverse stock split will reduce the current number of issued and outstanding shares of common stock from approximately\n16.267 million to approximately 1.084 million. Equitable adjustments will be made to the number of shares of the Company’s common\nstock issuable upon exercise of the Company’s equity awards, and warrants and the number of shares issuable under the Company’s\nequity incentive plans, as well as the applicable exercise prices for such equity awards and warrants, in accordance with their terms.\nIn addition, concurrent with the reverse stock split, a proportionate reduction will be made to the Company’s authorized shares\nof common stock such that the Company shall have 6,666,667 shares of authorized common stock after the effective time of the reverse stock\nsplit.\n\n \n\n1\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**SILO PHARMA, INC.**\n\n \n \n \n\nDate: June 1, 2026\nBy:\n/s/ Eric Weisblum\n\n \n \nEric Weisblum\n\n \n \nChief Executive Officer\n\n \n\n2"}